Given anti-PIV5 immunity in humans, anti-vector immunity may be a problem. Our recent studies indicate that pre-existing immunity to PIV5 does not negatively affect immunogenicity of a PIV5-based vaccine in dogs, demonstrating that pre-existing immunity is not a concern for using PIV5

as a vector. This result is consistent with the report that neutralizing antibodies against PIV5 do not prevent PIV5 infection in mice [13]. PIV5 has been used as a platform for developing vector-based vaccines against other viruses. A single-dose find more immunization of PIV5 expressing the rabies virus glycoprotein G protects mice against lethal rabies virus challenge [14]. Additionally, a single-dose inoculation of PIV5 expressing hemagglutinin (HA) or the NP protein of influenza virus protects against lethal H5N1 challenge in mice [15] and [16]. Importantly, intranasal Angiogenesis inhibitor administration of PIV5 is effective for eliciting robust mucosal immune responses [17], and is therefore

ideal for vaccinating against respiratory pathogens. Since an anti-RSV-F monoclonal antibody has been used to control RSV infection, it may be possible to develop an RSV vaccine by targeting RSV-F. Although several studies have implicated the G protein in RSV disease pathogenesis [18], [19], [20] and [21], prophylactic or therapeutic treatment with a monoclonal antibody (mAb 131-2G) specific to RSV-G mediates virus clearance and decreases leukocyte trafficking and IFN-γ production in the lungs of RSV-infected mice [22], [23], [24], [25] and [26]. In this study, we have tested the efficacies of recombinant PIV5 expressing RSV-F (rPIV5-RSV-F) or RSV-G (rPIV5-RSV-G) as potential vaccines in mice. BSR-T7 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 10% tryptose phosphate broth (TPB), 100 IU/mL penicillin, 100 μg/mL streptomycin (1% P/S; Mediatech Inc., Manassas, VA, USA), and 400 μg/mL G418 sulfate (Mediatech, Inc.). MDBK, BHK21,

and Vero cells were maintained in the same media without TPB much or G418. To construct the plasmids for rescuing rPIV5-RSV-F or rPIV5-RSV-G, the coding sequence of the green fluorescent protein (GFP) gene in the BH311 plasmid [27], containing GFP between HN and L of the full-length PIV5 genome, was replaced with the RSV-F or RSV-G gene, respectively. rPIV5-RSV-F and rPIV5-RSV-G were rescued as described previously [27]. PIV5, rPIV5-RSV-F and rPIV5-RSV-G were grown in MDBK cells as described previously [27]. RSV A2 and rA2-Luc (RSV A2 expressing Renilla luciferase) were grown in Vero cells as previously described [21]. Immunoprecipitation (IP) was performed as previously described [27]. A549 cells were infected with rPIV5-RSV-F or RSV A2 in 6-cm dishes. After 18–20 h, the cells were starved and metabolically labeled with 35S-Met and 35S-Cys for 3 h.